Supernus Pharmaceuticals Inc (NASDAQ:SUPN) was the target of some unusual options trading activity on Wednesday. Investors bought 906 call options on the stock. This represents an increase of 1,712% compared to the average daily volume of 50 call options.
A number of equities research analysts have recently issued reports on SUPN shares. Zacks Investment Research lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 26th. Piper Jaffray Companies set a $41.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “hold” rating in a research note on Sunday, October 29th. FBR & Co initiated coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $53.00 target price for the company. Finally, B. Riley reaffirmed a “buy” rating and set a $54.00 target price on shares of Supernus Pharmaceuticals in a research note on Thursday, January 18th. Four equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Supernus Pharmaceuticals has an average rating of “Buy” and a consensus target price of $51.36.
Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded up $0.05 during trading hours on Friday, reaching $37.20. 651,167 shares of the company traded hands, compared to its average volume of 776,314. The firm has a market capitalization of $1,910.00, a PE ratio of 33.82 and a beta of 1.08. Supernus Pharmaceuticals has a 52-week low of $24.65 and a 52-week high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The business had revenue of $80.40 million for the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. The firm’s revenue for the quarter was up 41.5% on a year-over-year basis. sell-side analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of the company’s stock in a transaction on Monday, January 22nd. The shares were sold at an average price of $48.04, for a total transaction of $960,800.00. Following the completion of the transaction, the vice president now directly owns 32,500 shares in the company, valued at $1,561,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total transaction of $2,178,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 165,750 shares of company stock valued at $7,133,973. Company insiders own 6.70% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Supernus Pharmaceuticals by 278.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after acquiring an additional 2,220 shares during the last quarter. Riverhead Capital Management LLC grew its position in shares of Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 1,462 shares during the last quarter. Advisor Group Inc. grew its position in shares of Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after acquiring an additional 410 shares during the last quarter. Victory Capital Management Inc. grew its position in Supernus Pharmaceuticals by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock valued at $148,000 after buying an additional 517 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado purchased a new position in Supernus Pharmaceuticals in the 4th quarter valued at $188,000. Institutional investors and hedge funds own 98.71% of the company’s stock.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.